<DOC>
	<DOCNO>NCT01469767</DOCNO>
	<brief_summary>The purpose study assess efficacy tolerability short-term treatment fluocinonide cream 0.1 % ( Vanos® ) treatment atopic dermatitis ( AD ) . Our hypothesis subject reduction Investigator 's Global Assessment score Day 7 Day 14 compare Baseline . Secondary objective include use actigraphy monitoring determine ability Vanos® cream reduce itch , thus nocturnal scratching , AD . Our hypothesis subject reduction nocturnal scratching activity , measure actigraphy movement count per hour , Day 7 Day 14 compare Baseline . Other secondary outcome measure include Eczema Area Severity Index ( EASI ) score , body surface area involvement , Visual Analog Scale itch , Subject Global Assessment . The investigator hypothesize measure improve Day 7 Day 14 compare Baseline . Medication adherence determine use objective adherence monitor . The investigator also hypothesize subject improve adherence topical medication AD , compare publish source , require use medication short define duration .</brief_summary>
	<brief_title>Efficacy Fluocinonide Cream 0.1 % ( Vanos ( R ) ) Reducing Itch Subjects With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Fluocinonide</mesh_term>
	<criteria>Male female mild severe atopic dermatitis , 12 year age old , agree participate provide write consent ( parent permission assent applicable ) . Have Investigator Global Assessment mild severe atopic dermatitis ( IGA rating 2 4 Investigator Global Assessment ) . Visual Analog Scale Itch score Baseline must great equal 50 100point scale . Percentage overall body surface area involvement ( BSA ) must ≥2 % . Women childbearing potential allow participate study , require use least one form birth control . Use within four week Baseline systemic anti‐inflammatory medication , may influence study outcome , systemic corticosteroid . Application use within two week Baseline topical corticosteroid medication topical anti‐inflammatory medication , may influence study outcome . Presence concurrent medical condition , determine investigator potentially interfere study outcome patient assessment . Introduction prescription medication , topical systemic , atopic dermatitis participate study . Use antihistamines participate study permit unless subject meet criteria antihistamine use VAS scale . Additionally , subject must remain stable dose antihistamine throughout study period . If patient meet criteria antihistamine use , note subject 's chart . Amount disease involvement would require &gt; 60 gm cream 1 week period . Subjects know allergy sensitivity topical Vanos® cream component . Pregnant woman Women breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>eczema</keyword>
	<keyword>itch</keyword>
	<keyword>scratch</keyword>
	<keyword>actigraphy</keyword>
	<keyword>adherence</keyword>
</DOC>